Financial news, markets, and business updates
The NIH is launching a new website design focused on core themes to simplify public access to health and biomedical research information.
Mary-Claire King shares her experience and thoughts on the impact of her work amidst the suspense of the Nobel Prize anticipation.
Despite increased access to addiction medications for youth, retention remains alarmingly low, raising urgent concerns among healthcare professionals.
Lilly adopts a direct-to-consumer model in Australia, bypassing traditional pharmacies to streamline access to its products.
Pharmacists face challenges in the orphan drug landscape, as policy gaps hinder personalized care for patients with specific conditions.
A firsthand account of heat-related incidents at the NYC Marathon highlights the urgent need for better medical planning in response to climate change.
Enrollees in Medicare Advantage plans for 2027 need to prepare for higher out-of-pocket expenses and fewer benefits during the upcoming enrollment period.
A recent special issue of Science highlights the need for more research in women's health, particularly on menopause, pain mechanisms, and beyond.
Explore the vibrant pulse of China's biotech sector, offering firsthand insights into its rapid advancements and ongoing challenges.
Blue Shield of California aims to adopt Medicare-inspired payment models, enhancing care for six million members by 2027.
The Trump administration's latest Medicare drug pricing rule falls short, while Eli Lilly's combination therapy shows significant weight loss results.
Invivyd's Phase 3 study shows its monoclonal antibody, VYD2311, offers better tolerability than the Pfizer vaccine, suggesting a potential alternative for Covid-19 protection.
Merck's recent decision to discontinue Recarbrio raises questions about the pharmaceutical industry's commitment to tackling antibiotic resistance.
The FDA has approved AbbVie's new oral medication for Parkinson's disease, marking a significant advancement in treatment options for patients.
GLP-1 drugs are now being marketed for general wellness rather than just obesity, while Merck and Daiichi face setbacks in cancer therapy approval.
Novo Nordisk blurs the line between medications and lifestyle enhancements with its GLP-1s, sparking debate over their true classification.
GLP-1 medications are shifting focus from medical obesity treatments to lifestyle products, reflecting a broader marketing strategy by companies like Novo Nordisk.
Recent cases reveal how AI technology can unintentionally facilitate bioweapons development, blurring the lines of scientific intent.
A U.N.-backed agency has partnered with 11 manufacturers to produce generic versions of Roche's flu treatment Xofluza, enhancing access in low-income nations.
Explore the implications of rising Chinese biotech development and the potential impact of FDA nominee Heidi Overton on U.S. drug regulation.